Ireland Generic Drugs Market By Type (Small Molecule Generics, Biosimilars), By Mode of Drug Delivery (Oral, Topical, Parenteral, and Others), By Form (Tablet, Capsule, Injection, and Others), By Source (In House, Contract Manufacturing Organizations), Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, and Others), By Distribution Channel (Hospital Pha
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIreland Generic Drugs Market By Type (Small Molecule Generics, Biosimilars), By Mode of Drug Delivery (Oral, Topical, Parenteral, and Others), By Form (Tablet, Capsule, Injection, and Others), By Source (In House, Contract Manufacturing Organizations), Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, and Others), By Distribution Channel (Hospital Pha
For instance, according to the global cancer observatory, in 2020, about 31,855 number of new cases in Ireland were of cancer. Out of which, 4503 were of prostate cancer, 3433 were of breast cancer, 3261 were of lung, 3178 were of colorectum, 1316 were of melanoma skin cancer, and 16154 were of other kind of cancers.
According to National Institute of Health, the prevalence of the four main categories of chronic diseases among adults in Ireland has been estimated to be 9.4% for asthma, 9.8% for Chronic obstructive pulmonary disease (COPD), 5.2% for diabetes, and 4.3% for Cardiovascular (CVD).
The growth of the Ireland generic drugs market can be attributed to the expanding healthcare infrastructure in the country and high investments by market players in developing generic drugs and medications, infectious disorders brought on by increased medical tourism, and environmental factors.
Furthermore, the ongoing research and development of technology in the production of medications is expected to aid the growth of the Ireland generic drugs market during the forecast period. The government supports the idea by increasing investment in the pharmaceutical sector. Moreover, pharmaceutical companies are compelled to manufacture pharmaceuticals products to meet the growing requirements in the country. Such factors are expected to bolster the growth of the Ireland generic drugs market during the forecast period.
Rising Prevalence of Chronic Diseases
According to the National Institute of Health, it isestimated that almost one million people are affected by one of the four main categories of chronic disease such as cardiovascular disease, chronic obstructive pulmonary disease, asthma, and diabetes.
According to the research articles, health experts say at least 50 percent of heart attack patients in the Ireland are under the age of 50
. For instance, the 2020 report of International Agency for Research on Cancer (IARC) estimated the incidence and mortality of cancers. Around 17453 new cancer cases were obtained in males and around 14402 new cancer cases were obtained in females. According to Irish Cancer Society, an estimated 44,000 people in Ireland get cancer each year.
Rise in Geriatric Population
The article published in ‘The Irish Times’ estimated the number of those population aged 80 and over were increased by 45 percent over the next ten years from 130,598 (2.8 percent of the population) in 2011 to 189,051 (3.5 percent of the population) in 2021
Download Free Sample Report
Government Initiatives
Ireland has implemented various initiatives to promote the use of generic drugs in the country's healthcare system. These initiatives aim to increase access to affordable and high-quality medicines, improve patient outcomes, and reduce healthcare costs. The first significant initiatives were the introduction of the Health (Pricing and Supply of Medical Goods) Act 2013, which established a system of reference pricing and generic substitution in Ireland. Under this system, the price of a medicine is set by reference to the price of the lowest-priced medicine in a group of interchangeable products. This encourages pharmacies to dispense the lowest-priced generic medicine found at, rather than a more expensive branded product.
In December 2021, Medicines for Ireland (MFI) signed a new framework agreement on the supply and pricing of non-originator, generic, biosimilar, and hybrid medicines to be implemented between 2021‒2025. The agreement between MFI and the Department of Health, the Department of Public Expenditure and Reform, and with the Health Service Executive (HSE) attributed to deliver improved access to new and innovative medicines that causes reductions in the cost of existing medicines, increased security of supply, and an overall easing of financial pressure on the health services across Ireland into the future.
For example, the "Switch to Save" campaign was launched in 2014 to encourage the use of generic drugs in the treatment of high blood pressure, high cholesterol, and gastroesophageal reflux disease (GERD).
Market Segmentation
The Ireland generic drugs market is segmented by type, mode of drug delivery, form, source, application, distribution channel, and region. Based on type, the market is further bifurcated into small molecule generics and biosimilars. Based on mode of drug delivery, the market is segmented into oral, topical, parenteral, and others. Based on form, the market is further bifurcated into tablet, capsule, injection, and others. Based on source, the market is further bifurcated into in house and contract manufacturing organizations. Based on application, the market is segmented into cardiovascular diseases, diabetes, neurology, oncology, anti-inflammatory diseases, and others. Based on distribution channel, the market is bifurcated into retail pharmacies, hospital pharmacies, online pharmacies, and others.
Market Players
Teva Pharmaceutical Industries Ltd. Ireland, Novartis Ireland, Fresenius Kabi Ireland, Aurobindo Pharma (Ireland) Limited, Novo Nordisk Ireland, Abbott Ireland Limited, Sanofi Aventis Ireland Ltd., Aspen Pharma Ireland Limited, Johnson & Johnson Ireland Limited, and Takeda Pharmaceuticals Ireland Limited are some of the leading companies operating in the Ireland generic drugs market.
| Attribute | Details |
| Base Year | 2022 |
| Historical Years | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in Units and CAGR for 2017-2021 and 2022E-2028F |
| Report Coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Type Mode of Drug Delivery Form Source Application Distribution Channel Region Company |
| Region Scope | Northern Ireland, North-West, West, Midland East, Dublin, Shannon, South-East, Cork-Kerry |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd. Ireland, Novartis Ireland, Fresenius Kabi Ireland, Aurobindo Pharma (Ireland) Limited, Novo Nordisk Ireland, Abbott Ireland Limited, Sanofi Aventis Ireland Ltd., Aspen Pharma Ireland Limited, Johnson & Johnson Ireland Limited, Takeda Pharmaceuticals Ireland Limited |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy